Citations

Showing 10 of 108081 citations.

Go with the Flow to Maximize Clot Ingestion
Brinjikji, Waleed , Wainwrights, John, Contrares, Mayra, Chesler, Naomi C.

Mayo Clinic

The Arab Journal of Interventional Radiology | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0043-1763454 Get It

Percutaneous Transesophageal Gastric Catheters: A Single Institution Experience
Zaazoue, Karim Ahmed, Core, Jacob , Devcic, Zlatko , Frey, Gregory, Wallace, Alex , McKinney, J. Mark , Coltvet, Lisa Rotellini , Toskich, Beau , Ritchie, Charles , Zaazoue, Karim A. , Elboraey, Mohamed, Frey, G. , Wallace, Alex

Mayo Clinic

The Arab Journal of Interventional Radiology | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0043-1763436 Get It

Structure-based design and characterization of Parkin-activating mutations
Stevens, Michael , Croteau, Nathalie , Eldeeb, Mohamed A. , Zeng, Zhi Wei , Toth, Rachel , Durcan, Thomas M. , Springer, Wolfdieter , Muqit, Miratul M. K. , Trempe, Jean‐François , Toth, Rachel , Springer, Wolfdieter , Fon, Edward A , Muqit, Miratul Mk , Trempe, Jean-François , Antico, Odetta

Mayo Clinic

Life Science Alliance | March 20, 2023 | Volume: 6 | Issue: 6 | Pages: e202201419

10.26508/lsa.202201419 | PMID 36941054 Get It

Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibiting moderate effect on normal stem cells growth
Stoellinger, Heidi, Quiñones‐Hinojosa, Alfredo , De Araujo Farias, Virginea, Alexanian, Arshak R. , Stoellinger, Heidi Marie, Farias, Virgínea

Mayo Clinic

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2698139/v1 | PMID 36993520 Get It

Abstract Glioblastomas (GBM), also known as glioblastoma multiforme, are the most aggressive type of brain cancers. Currently, there is no real treatment for GBM and thus there is a compelling need for new therapeutic strategies for such type of cancers. Recently, we demonstrated that specific combinations of epigenetic modifiers significantly affect the metabolism and proliferation rate of two most aggressive GBM cell lines D54 and U-87. Importantly, these combinations exhibited minimal effect on normal stem cells growth. In this study we demonstrated that the combinations of modulators of histone and DNA covalent modifying enzymes that synergistically suppress D54 and U87 cell lines growth, also impair the viability of a patient freshly-derived GBM stem cell line. These data suggest that epigenetic modifiers alone or in specific combinations exhibit cytotoxic effect on established and low passage patient derived GB cell lines and thus could be a promising therapeutic approach for such type of brain cancers.
JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders
Ambrus-Aikelin, Geza, Takeda, Katsuyuki , Joetham, Anthony, Lazić, Miloš , Povero, Davide , Santini, Angelina M., Pranadinata, Rama F., Johnson, Casey D. , McGeough, Matthew D., Beasley, Federico C., Stansfield, Ryan, McBride, Christopher, Trzoss, Lynnie, Hoffman, Hal M. , Feldstein, Ariel E., Stafford, Jeffrey A., Veal, James M., Gelfand, Erwin W. , Stansfield, Ryan K., Bain, Gretchen

Mayo Clinic

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2652913/v1 Get It

Abstract The NLRP3 inflammasome is an intracellular, multiprotein complex that promotes the auto-catalytic activation of caspase-1 and the subsequent maturation and secretion of the pro-inflammatory cytokines, IL-1β and IL-18. Persistent activation of the NLRP3 inflammasome has been implicated in the pathophysiology of a number of inflammatory and autoimmune diseases, including neuroinflammation, cardiovascular disease, non-alcoholic steatohepatitis, lupus nephritis and severe asthma. Here we describe the preclinical profile of JT002, a novel small molecule inhibitor of the NLRP3 inflammasome. JT002 potently reduced NLRP3-dependent proinflammatory cytokine production across a number of cellular assays and prevented pyroptosis, an inflammatory form of cell death triggered by active caspase-1. JT002 demonstrated in vivo target engagement at therapeutically relevant concentrations when orally dosed in mice and prevented body weight loss and improved inflammatory and fibrotic endpoints in a model of Muckle-Wells syndrome (MWS). In two distinct models of neutrophilic airway inflammation, JT002 treatment significantly reduced airway hyperresponsiveness and airway neutrophilia. These results provide a rationale for the therapeutic targeting of the NLRP3 inflammasome in severe asthma and point to the use of JT002 in a variety of inflammatory disorders.
Robotic bronchoscopy: potential in diagnosing and treating lung cancer
Duke, Jennifer D. , Reisenauer, Janani

Mayo Clinic

Expert Review of Respiratory Medicine | March 20, 2023 | Volume: 17 | Issue: 3 | Pages: 213-221

10.1080/17476348.2023.2192929 | PMID 36939545 Get It

Acute Type A Aortic Dissection in Under 30 Years: Demographics, Etiology, and Postoperative Outcomes of 139 Patients
Luehr, Maximilian , G., Willems Charles, Polycarpou, Andreas , Jassar, Arminder S. , Kreibich, M., Dohle, D. S., Weiss, G., Hagl, C., Martens, Andreas , Osada, Hiroaki, Tsagakis, K., Yıldız, Murat , Ma, W. G., Heck, Roland , Kreibich, Maximilian , Dohle, Daniel‐Sebastian , Rega, Filip , Schachner, Thomas , Corte, Alessandro Della , Schoenhoff, Florian

Mayo Clinic

The Thoracic and Cardiovascular Surgeon | March 20, 2023 | Volume: 71 | Issue: S 01 | Pages: S1-S72

10.1055/s-0043-1761658 Get It

Translamina Access via a Bifrontal Approach to a Hypothalamus Cavernous Malformation
Vilany, Larissa , Leonel, Luciano P.C., Link, Michael J., Celda, María Peris, Link, Michael J. , Pinheiro‐Neto, Carlos , Lanzino, Giuseppe

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762547 Get It

Endoscopic Endonasal Approach: Recurrent Fibrous Pituitary Adenoma with Cavernous Sinus Extension
Perez‐Vega, Carlos , Samson, Susan L. , Olomu, Osarenoma , Quiñones‐Hinojosa, Alfredo , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762525 Get It

Surgical Treatment of Hemifacial Spasm via Microvascular Decompression of a Large, ECTATIC Vertebral Artery
Bauman, Megan M., Link, Michael J., Carlstrom, Lucas P. , Link, Michael J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762510 Get It